CTi Biopharma Corp

CTi Biopharma — Investor Presentation (January 2017)

36 slides from CTi Biopharma's investor presentation, Jan 9, 2017

  1. Slide 1: Corporate Presentation

    Conquering cancer. That’s in our blood. CORPORATE PRESENTATION San Francisco – January 9, 2017 © Copyright 2017 CTI BioPharma Corp. All rights reserved.

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a

  3. Slide 3: Our Pipeline – Deep Hematology Expertise

    Our Pipeline – Deep Hematology Expertise 3 Program Indication Phase 1 Phase 2 Phase 3 Approved Partner Pacritinib PERSIST-1: Myelofibrosis (all platelet counts) Unpartnered PERSIST-2: Myelofibrosis (platelets ≤100K/µL) PAC203: Dose exploration study PIXUVRI® (pixantrone) Aggressive B-cell NHL, 3rd-4

  4. Slide 4: Pacritinib

    Pacritinib • Orphan designation for myelofibrosis (FDA and EMA) • Patent protection through 2026/29 plus possible patent term extension An oral kinase inhibitor with selectivity for JAK2 and FLT3 4 1. Singer J, et al. ASH, 2014, Abstract 1874. CSF1R, colony stimulating factor 1 receptor; FLT, FMS-li

  5. Slide 5: Myelofibrosis: A Chronic Disease

    Myelofibrosis: A Chronic Disease • Malignant bone marrow disorder • Activation of JAK2 pathway triggers an inflammatory response, bone marrow scarring • Poor QOL: enlargement of the spleen, anemia, thrombocytopenia, extreme fatigue, pain, severe itching, drenching night sweats and GI side effects •

  6. Slide 6: Thrombocytopenia and MF

    Thrombocytopenia and MF 1. Platelet distribution for patients in Europe is similar to US. 2. Platelet distribution based on Visani et al. 1990 Br J Haematol; Caramazza et al. 2011 Leukemia; Tam et al. 2009 JCO. 3. Based on Mehta, et al. 2014 Leukemia & Lymphoma. “When you combine disease-related and

  7. Slide 7: Pacritinib Targets Major Unmet Needs

    Pacritinib Targets Major Unmet Needs 7 • Despite baseline platelets ≤100K/µL excluded in COMFORT trials1, dose reductions (52%) at ≤12 weeks of therapy due to anemia and/or thrombocytopenia2 • Most patients (85%) who discontinue frontline rux received no further Rx, 7 month median OS3 1. Verstovsek,

  8. Slide 8: PERSIST-1 Phase 3 Study Design

    Study Centers: Europe, Australia, New Zealand, Russia and U.S. Enrolled: 327 patients Results: Topline March 2015; oral presentations at ASCO and EHA 2015 Principal Investigators: Ruben Mesa, M.D., Mayo Clinic, Arizona Claire Harrison, M.D., Guy’s Hospital, London *Cross-over from BAT allowed after

  9. Slide 9: PERSIST-1 Phase 3 Results: Highlights

    PERSIST-1 Phase 3 Results: Highlights Primary Endpoint: • Significantly more patients achieved ≥35% spleen volume reduction (SVR), regardless of baseline platelet count (p=0.0003, ITT population) Low Platelet Subset: • Significant SVR also observed in highest-risk predefined subset (baseline platele

  10. Slide 10: Overall Survival by Treatment

    Overall Survival by Treatment 10 • OS was not significantly different between arms, and potentially confounded by a large percentage (84%) of pts crossing over at 24 weeks Mesa RA, et al., ASCO 2016. Abstract LBA7065.

  11. Slide 11: PERSIST-1: Most Common Adverse Events

    PERSIST-1: Most Common Adverse Events 11 AE, adverse event; BAT, best available therapy, excluding ruxolitinib; PAC, pacritinib. All Grades Grade 3 Grade 4 Adverse Event, n (%) PAC (n=220) BAT (n=106) PAC (n=220) BAT (n=106) PAC (n=22) BAT (n=106) Non-hematologic (>10%) Diarrhea 117 (53.2) 13 (12.3)

  12. Slide 12: PERSIST-2 Phase 3 Study Design

    Sites: North America, Europe, Australia and New Zealand PI: Serge Verstovsek, MD Anderson Cancer Center, Houston, TX Patient Enrollment: Completed January 2016 Clinical Hold: Imposed February 2016, lifted January 2017 Results: Topline Aug. 2016; presented as ASH 2016 oral late breaker by Lead invest

  13. Slide 13: ITT Population and Efficacy Results

    ITT Population and Efficacy Results • ITT (n=311) – safety - PAC 211 (QD 104 + BID 107); BAT 100 • ITT FAS1 (n=221) – efficacy - PAC 149 (QD 75 + BID 74); BAT 72 13 Co-Primary: Pac BID+QD Secondary: Pac BID Secondary: Pac QD BAT SVR 18% (p = 0.001) 22% (p = 0.001) 15% (p = 0.017) 3% TSS 25% (p = 0.0

  14. Slide 14: BAT Choices and Crossover Data

    BAT Choices and Crossover Data • Patients could switch to a different BAT regiment during treatment • Crossover allowed at Week 24, or with documented progression - 50% of BAT patients crossed over to pacritinib, 86% at or after Week 24 14 BAT Ruxolitinib 45% Ruxolitinib only 33% Watch and Wait 30%

  15. Slide 15: Efficacy in BAT Arm

    Efficacy in BAT Arm • Ruxolitinib starting dose: - 5 mg / d (69%) - 10 mg / d (19%) - 15 mg / d (6%) - 20 mg / d (6%) • 32 / 44 (73%) required dose interruptions, reductions or discontinuations 15 Efficacy Pac QD (n = 75) Pac BID (n = 74) BAT: Rux (n = 32) BAT: Other (n = 40) SVR 15% 22% 3% 3% TSS 1

  16. Slide 16: Overall Survival (Censored at Clinical Hold)

    Overall Survival (Censored at Clinical Hold) 16 Overall Survival PAC QD (n=104) PAC BID (n=107) BAT (n=100) Events, n (%) 15 (14) 10 (9) 14 (14) Log-rank P value, vs BAT 0.662 0.346 - HR (95% CI), vs BAT 1.18 (0.57-2.44) 0.68 (0.30-1.53) - Mascarenhas J, et al., ASH 2016. Abstract LBA-5.

  17. Slide 17: Most Common TEAEs

    Most Common TEAEs 17 Characteristic PAC QD n=104 PAC BID n=106 BAT n=98 Pts with ≥1 TEAE 104 (100) 100 (94) 87 (89) Diarrhea 70 (67) 51 (48) 15 (15) Nausea 39 (38) 34 (32) 11 (11) Thrombocytopenia 34 (33) 36 (34) 23 (23) Anemia 29 (28) 25 (24) 15 (15) Vomiting 22 (21) 20 (19) 5 (5) Adverse Events we

  18. Slide 18: Serious TEAEs

    Serious TEAEs 18 PAC QD n=104 PAC BID n=106 BAT n=98 Any SAE, n (%) 48 (46) 50 (47) 30 (31) Most common SAEs (≥5 in any arm), n (%) Anemia 5 (5) 8 (8) 3 (3) Thrombocytopenia 2 (2) 6 (6) 2 (2) Pneumonia 5 (5) 6 (6) 4 (4) Renal failure, acute 5 (5) 2 (2) 2 (2) SAEs of interest, n (%) CHF 1 (1) 4 (4) 2

  19. Slide 19: Summary of Deaths

    Summary of Deaths 19 PAC QD n=104 PAC BID n=107 BAT* n=100 ITT, censored at the time of full clinical hold Deaths 15 (14) 10 (9) 14 (14) Due to AEs Cardiac AEs Bleeding AEs 8 (8) 2 (2) 0 4 (4) 0 3 (3) 6 (6) 2 (2) 1 (1) Due to PD 5 (5) 5 (5) 7 (7) Other 2 (2) 1 (1) 1 (1) After the full clinical hold

  20. Slide 20: Clinical Hold Lifted Jan. 2017

    Clinical Hold Lifted Jan. 2017 • PAC203 trial to evaluate safety and efficacy of 3 dose regimens of pacritinib - Patients will be randomized to 100 mg QD, 100 mg BID or 200 mg BID - Treatment designed to continue for 24 weeks - Expected to enroll up to approximately 105 - Study expected to initiate

  21. Slide 21: Regulatory Strategy

    Regulatory Strategy • Pursue application for treatment of myelofibrosis patients who are ineligible to receive, intolerant of or have insufficient response to ruxolitinib • MAA on file with EMA - At time of filing only PERSIST-1 data was available - Evaluating whether to update the current applicati

  22. Slide 22: PIXUVRI

    PIXUVRI PIXUVRI®

  23. Slide 23: PIXUVRI: Fulfilling An Unmet Clinical Need

    • Palliative care (symptom control) or clinical trials • Pixuvri approved in EU for 3rd-4th line agg. B-cell NHL PIXUVRI: Fulfilling An Unmet Clinical Need 23 1st Line 2nd Line 3rd Line+ ® ( P I X A N T R O N E ) • Typically anthracycline- based treatment R-CHOP • Curative in 50% - 55% of patients1

  24. Slide 24: PIXUVRI: PIX306 Study

    PIXUVRI: PIX306 Study Eligibility Criteria Relapse after CHOP-R therapy or an equivalent regimen and are ineligible for stem cell transplant 1:1 Randomization Primary Endpoint PFS Secondary Endpoints CR ORR OS Gemcitabine Rituximab Pixantrone Rituximab Post-marketing Commitment Phase 3 Study • Sites

  25. Slide 25: Tosedostat

    & Tosedostat

  26. Slide 26: Tosedostat: A Novel Treatment for MDS & AML

    Tosedostat •Oral, once-daily, aminopeptidase inhibitor •Interferes with protein recycling by preventing breakdown of peptides into amino acids necessary for tumor cell survival •Synergy with targeted agents (HMA, proteosome inhibitors) or chemotherapy •Several Phase 2 ISTs in AML or MDS underway A N

  27. Slide 27: Tosedostat Clinical Data in AML

    Tosedostat Clinical Data in AML Promising CR Rates in Three Phase 2 Trials • Encouraging data from monotherapy in AML relapse: OPAL study1 (Cortes, MD Anderson) - ORR 22%; AE’s mild and manageable • LDAC* or decitabline + tosedostat in 1st line elderly (n=34)2 (Pagel, UW) - CR/CRi 53%, well-tolerate

  28. Slide 28: Financial Overview

    Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Market Capitalization* ~$125 mm Shares Outstanding as of 12/31/16 ~28mm Cash and Equivalents as of 12/31/16** ~$52mm Debt as of 12/31/16 $19.5mm *Based on stock price stock price of $4.46 per share as of Jan

  29. Slide 29: 2017 Goals

    2017 Goals • Initiate FDA-required dose exploration study for pacritinib– Q2 • Obtain ex-U.S. partner for pacritinib and thereby obtain cash to fund the company into 2018 – 2H • Regulatory progress with FDA and EMA for pacritinib– YE • Announce top-line PIX306 results - YE 29

  30. Slide 30: Investment Opportunity

    Investment Opportunity • Pacritinib: Potential opportunity to address major unmet need in myelofibrosis; working towards meaningful regulatory progress in 2017 • Pixuvri: Phase 3 readout in 2017; opportunity to expand indication in Europe and potential for US approval • Focus on shareholder value: -

  31. Slide 31: Thank You!

    Thank You! Investor Contact: Ed Bell Sr. Director, Investor Relations ebell@ctibiopharma.com 206-272-4345 31

  32. Slide 32: Supplemental Information

    Supplemental Information

  33. Slide 33: PERSIST-2 OS (Jan '16 cutoff)

    PERSIST-2 OS (Jan ‘16 cutoff) 33 Data cutoff: Jan 26, 2016 Unblinded to CTI in Aug 2016 0.5017

  34. Slide 34: PERSIST Trials Patient Demographics

    PERSIST Trials Patient Demographics PERSIST: Aggressive disease, high symptom burden 34 PERSIST-1 (n=220) PERSIST-2 (n=211) Primary / Secondary1 65% / 35% 68% / 32% Median time from Dx 1.0 y 2.3 y Median platelets 169,500 65,000 Platelets <100K / µL 33% 100% Hgb <100 g / L 38% 61% 1. Real world MF p

  35. Slide 35: SVR and OS Correlation

    SVR and OS Correlation SVR Pac BID+QD OS HR (95% CI, n) Pac BID HR (95% CI, n) Pac QD HR (95% CI, n) BAT HR (95% CI, n) ≥ 35% 0.103 (0.014, 0.772) (n=27) 0.000 (0.000, NA) (n=16) 0.193 (0.025, 1.519) (n=11) 1.555 (0.198, 12.195) (n=2) ≥ 20 to <35% 0.091 (0.012, 0.681) (n=31) 0.000 (0.000, NA) (n=19)

  36. Slide 36: SVR and OS Correlation

    SVR and OS Correlation OS by Week 24 SVR - Pooled pacritinib arms 36

CTI Biopharma — Investor Presentation (January 2017) on 6ix